Switch to
More onapp

Kilitch Drugs (India) Ltd

KILITCH
Health CarePharmaceuticals
SmallcapWith a market cap of ₹257 cr, stock is ranked 1,664
Moderate RiskStock is 2.83x as volatile as Nifty
162.402.70 (-1.64%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹257 cr, stock is ranked 1,664
Moderate RiskStock is 2.83x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
24.43
PB RatioPB Ratio
1.45
Dividend YieldDiv. Yield
Sector PESector PE
35.84
Sector PBSector PB
4.35
Sector Div YldSctr Div Yld
0.89%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Kilitch Drugs (India) Limited is an India-based company, which is engaged in the development and operations of its pharmaceutical business. The Company primarily offers ONECEF INJ.1GM and KILITCH SRO 20.80GMS. The Company's parenteral solutions include Hyoce, Metoclop, K-Suxa, Kytoin, Artim, Neticin, Klavmox, Kilox, Clinda, Flork, Adron, Pivac, Ergomet, Kilmeta, Zovikil, Bivadin, Dexo, Dokine, Kain, K-Fol, Kiol, Vankom, Kabalin, Chlorpheniramine, Mectin, Cybuta, Onecef, Carboplatin Injection, Paclitaxel Injection, Snake Venom Antiserum (Lyophilized), Gas Gangrene and Carboxymethylcellulose Sodium Ophthalmic solution. Its effervescent products include ROIPAR, DUREGRA and ROIVIT. The Company's nutritional product range includes Celtine. The Company offers medical devices, such as C-Seal. The Company offers products for various categories, such as gastroenterology, non-steroidal anti-inflammatory drugs, anticonvulsant/antiepileptic, anti-inflammatory, anti-malarials and aminoglycosides.

Financial TrendFinancial statements 

2019202020212022100.9466.4874.21109.7214.774.456.1510.53
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Newspaper Advertisements 
Announced OnNov 16, 2022

Newspaper publication pertaining to the extract of the financial results of the Company for the quarter ended 30th September, 2022. The said extract of the financial results was published on Marathi and English edition on 15th November, 2022. | Download

Newspaper publication pertaining to the extract of the financial results of the Company for the quarter ended 30th September, 2022. The said extract of the financial results was published on Marathi and English edition on 15th November, 2022. | Download

Outcome of Board Meeting 
Announced OnNov 14, 2022

Kilitch Drugs (India) Limited has informed the Exchange about Board Meeting held on 14-Nov-2022 to consider financial statements for the period ended September 2022 | Download

Kilitch Drugs (India) Limited has informed the Exchange about Board Meeting held on 14-Nov-2022 to consider financial statements for the period ended September 2022 | Download

Cash Dividend 
Ex. DateSep 20, 2019

Final • Div/Share: ₹ 0.5

See all events